Overview
- HHS approved removing the strictest "black box" warnings from three estradiol transdermal patch labels, a development reported by Reuters, Healio and The Independent on Friday, Oct. 30, 2026.
- The action extends an FDA effort that in February cleared six menopausal hormone therapy products of warnings about cardiovascular disease, breast cancer and probable dementia.
- Federal officials say the FDA has been working with manufacturers since September to boost patch supplies and that estrogen patch market output has doubled over the past year, according to Dorothy Fink of the NICHD.
- The FDA has expedited review of 10 manufacturer supplement requests this year to allow production changes and approved two of those requests within the past week, Sarah Ibrahim said.
- Brand names for the three updated patches were not disclosed and Reuters has previously reported shortages of some injectable and vaginal estrogen products, so patients and clinicians should watch pending supplement approvals and manufacturer capacity for signs of improved availability.